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Abstract: Stem cell therapy is an exciting and upcoming branch of tissue engineering with application in the field of 
orthopaedics. The most commonly used type of stem cells, mesenchymal stem cells (MSCs), can be easily isolated from 
bone marrow or synovium and cultured in vitro. Newer techniques using tissue engineering to regenerate musculoskeletal 
tissue by using biomimetic materials are now being studied. These osteoconductive three dimensional constructs seeded 
with MSCs are highly porous, biodegradable and biomechanically stable scaffolds which do not evoke an immunogenic 
host cell response. Research has shown the importance of growth factors in guiding and modulating the differentiation of 
MSCs in order to obtain the required cell type. Gene-based delivery systems have aided the delivery of sustained 
quantities of these growth factors. The evidence from growth factor enhanced tissue engineering studies for tissue healing 
looks very positive. This is a multi-disciplinary approach that integrates molecular, biochemical and clinical techniques 
with developmental and engineering processes. Initial studies indicate an immense potential for cell based strategies to 
enhance current orthopaedic approaches in skeletal tissue reconstruction. Ultimately, there is a need for randomised 
controlled trials on human populations to apply these findings to a clinical setting. Nevertheless, stem cell based tissue 
engineering in orthopaedics shows a promising future. 
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  Much of the interventions in orthopaedics today aim 
towards the restoration of normal function by replacing 
damaged tissues or organs in such a way so as to achieve 
effective, long-lasting and stable repair [1]. A number of 
traditional therapeutic approaches to repair skeletal tissue 
have been developed and hypothesised, but they have all 
presented with a variety of shortcomings. For example, using 
bone grafts to repair large segmental bone defects [2], 
extensive bone loss or destruction [3] and avascular necrosis 
[4] still poses several challenges. Autologous bone graft, 
which is commonly used, has the disadvantages of limited 
availability, donor site morbidity, pain, infection and 
neurovascular injury [5]. The gold standard in bone repair 
remains sterilised human allogenic bone graft, i.e. tissue 
donated from other human individuals [6]. However, due to 
poor osseointegration of allografts, failure rates of up to 30% 
have been seen [7]. 
  Another example is articular cartilage damage as a result 
of trauma or chronic degenerative changes. Cartilage heals 
very poorly, owing to the lack of intrinsic regenerative 
capacity of the chondrocytes and its poor vascular supply. In 
addition, the repaired tissue is more fibrous and 
mechanically inferior to normal hyaline cartilage resulting in 
an inadequate physiological repair [8]. Traditional surgical 
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  Amidst this, tissue engineering using stem cells has 
emerged as a hot topic of research and is a promising 
alternative to the traditional techniques of bone grafting. 
This method aims to regenerate rather than repair skeletal 
tissue defects. A stem cell is an immature or undifferentiated 
cell which is capable of producing identical daughter cells of 
specific cell lineages [9, 10]. Stem cells have numerous 
advantages over mature cells for tissue regeneration. Mature 
cells lack the capacity to extensively self-renew or 
proliferate in order to generate sufficient yield. They are also 
limited to a particular phenotype and are thus, usually unable 
to transdifferentiate into the desired cell lineage upon 
stimulation. 
SOURCES OF STEM CELLS IN SKELETAL TISSUE 
REGENERATION 
  Mesenchymal stem cells are multipotent and have ability 
to self-renew and proliferate over generations without 
significant loss of their characteristics [11]. They do not 
present with the ethical and legal concerns associated with 
embryonic stem cells and unlike committed chondrocytes 
isolated from hyaline cartilage, they retain their 
transdifferentiation capability. MSCs were first described in 
the 1960s by Friendenstein et al. [12]. They demonstrated 
that rare clonogenic cells isolated from adult rodent bone 
marrow (BM) aspirates [13] rapidly proliferated in vitro 
giving rise to distinct colonies, i.e. fibroblastic colony-
forming units (CFU-F). These colonies, derived from a 
single precursor cell, can differentiate into all the different 
cell lineages of the limb mesoderm (osteoblasts, 
chodrocytes, adipocytes etc.) [14]. This property gives the 
potential to generate virtually billions of ex vivo-expanded 
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  Tissue engineering is a multidisciplinary area of research. 
It aims to regenerate tissue by the implantation of cells 
grown ex vivo, or by stimulating the cells to grow into an 
implanted matrix [15]. The ex vivo expansion of these cells 
into all types of mesenchymal tissue is paramount to the 
success of cell-based tissue engineering. MSC-based therapy 
can be used for tissue regeneration by both site-specific 
(localised) and systemic applications. 
  Its basic principle involves the use of living cells with a 
natural or synthetic support, or scaffold, to produce a three-
dimensional (3D) living tissue construct that is implantable 
and can facilitate a faster rate of tissue repair or fill recipient 
tissue site. To engineer the new tissue, donor cells are first 
isolated, harvested and seeded onto the scaffold. The next 
step is the stimulation of cell proliferation and then the 
maintenance of cellular differentiation. Finally, the living 
tissue is implanted into the patient in order to obtain the 3D 
construct containing the newly seeded living cells in vivo. 
MSCs are a useful cell source in tissue engineering due to 
their innate capacity for regeneration and their ability to be 
easily isolated and expanded using culture techniques. 
  An ideal tissue engineering scaffold should have some 
key properties such as being osteoconductive if filling bone 
site. It should be fully biodegradable, porous, 
biomechanically stable and non-immunogenic to the host site 
[16]. Natural biomaterials facilitate better cell attachment, 
differentiation and function, however, they may vary from 
batch-to-batch and have difficulties in scaling up by ex vivo 
expansion of the MSCs. Synthetic biomaterials, on the other 
hand (of which polyactides are the most widely used), can be 
engineered according to precise specifications but may not 
always interact with cells in the desired way. Hence, a 
biomimetic material which can combine the advantages of 
both natural and synthetic biomaterials is an ideal scaffold 
for cell-based tissue engineering. 
  In a study by Yoon et al. [17], a fully absorbable 
osteogenic poly (DL-lactide-co-glycolide) (PLGA) scaffold 
seeded with MSCs was used to repair intercalated bone 
defects in vivo. Biomaterials can be rendered osteoinductive 
in several ways and, in this case, the scaffold was loaded 
with calcitriol, which is shown to induce mineralisation of 
the bone tissue [18]. The appropriate level of calcitriol in the 
pores is crucial to support proliferation and differentiation of 
the cells into osteoblasts. Calcitriol-loaded PLGA scaffolds 
seeded with/without MSCs were implanted in an animal 
model of a bone defect. Radiograph assessments showed that 
only the calcitriol-loaded groups showed bony union at 9 
weeks. Also, RT-PCR and histological studies confirmed the 
development of new osteoid matrix and direct calcium 
deposits contributing to successful regeneration of the bony 
defects. At 20 weeks, complete bony union was achieved. 
The MSCs not only enhanced osteoconduction of the 
implanted scaffold via  angiogenic activation of the host 
cells, but also underwent differentiation. The PLGA scaffold 
also degrades completely in 8 weeks without leaving residual 
metabolites due to its high porosity [19]. 
  However, whether the MSCs themselves differentiated 
into osteoblasts directly or they promoted angiogenesis of 
the scaffold remains uncertain. Nevertheless, this fully 
absorbable synthetic bone graft biomaterial along with 
marrow stem cells does provide a hopeful allogenic graft 
substitute to repair large bone defects. 
  Hydroxyapatite (HA) has been used extensively in 
orthopaedics, particularly with promoting osteoconduction of 
prosthesis. Maracci et al. [3] investigated the use of HA-
coated ceramic scaffolds seeded with MSCs to repair long 
bone defects. The MSCs were expanded in vitro and seeded 
onto the scaffolds. These were placed in the long bone 
defects of four patients. The patients were followed up over 
6-7 years and evaluated using radiographs at fixed intervals. 
The results showed integration of implants with host bone, 
new bone formation inside bioceramic pores and vascular 
ingrowth. However these outcomes were all progressive. 
Seven months after implant surgery, complete fusion and full 
functional recovery of the limbs was achieved. This was less 
than half the recovery time compared to the traditional bone 
allograft. 
  Future strategies in this field would be to use more ideal 
costructs like PLGA which provide the initial support but is 
resorbed at a similar rate to new bone deposition in the 
scaffold. It should also provide more stable fixation and site-
specific formation of new bone as shown in animal studies 
using porous calcium phosphate-based scaffolds [20, 21]. 
Ultimately, there is a need for randomised controlled trials 
after performing more animal studies to apply this to a 
clinical setting. In addition, the cost benefit ratio will also 
need to be considered after sufficient trials have been carried 
out to validate the use of this technology over traditional 
methods of bone reconstruction [2]. 
GROWTH FACTORS IN ORTHOPAEDICS 
  Bone volume is determined by the relative rates of bone 
formation and resorption. Growth factors are protein 
signalling agents that act locally to stimulate formation and 
proliferation of osteoblasts [22]. The multilineage potential 
of MSCs occurs under guided differentiation to obtain the 
required cell type. This can only be achieved under the 
modulation of appropriate growth factors [23]. Once 
damaged, chondrocytes, especially from articular cartilage 
have only a limited capacity in self-repair [24]. The use of 
growth factors extends to regeneration of muscle, tendon, 
ligament and connective tissue. Hence, growth factors are 
used to retain MSCs’ proliferative capacity and 
differentiation potential, which is lost during their ex vivo 
expansion. However, delivering sufficient quantities of 
growth factor locally in a sustained manner has proven 
difficult until the advent of gene transfer technology. 
Combining this gene-based delivery system with tissue bio-
engineering is a potential approach to achieving more 
biologically active product at the site of the defect than that 
delivered by exogenous recombinant proteins [25]. 
  There are a number of growth factors used for 
regenerative applications in orthopaedics. Some of these will 
be discussed here. 
1. Bone Morphogenetic Protein (BMP) 
  The autograft contains not just the stem cells and the 3D 
scaffold, but also osteoinductive growth factors, of which 
human Bone Morphogenetic Protein (BMP) is now 
frequently used since it was first described by Urist about 40 
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haematopoietic cell differentiation [27]. Gene transfer 
provides a good method to deliver the BMP signal in a 
sustained manner [28]. In a study by Evans et al, grafts of 
muscle or fat were transduced with BMP-2 using an 
adenovirus vector [29]. The gene-activated fat and muscle 
were able to heal significantly sized osteochondral defects in 
rabbit models. Both these tissues possess an intrinsic 
capacity to regenerate into bone and other connective tissue 
because they possess osteoprogenitor cells and are able to 
serve as scaffolds. The healing occurs by an endochondral 
process [30]. Histological evidence showed a rapid and 
efficient conversion of muscle into cartilage [29]. The 
transplanted graft induces the formation of osteoblasts from 
host osteoprogenitor cells, as also demonstrated by 
Gerstenfeld et al. [31]. 
  BMPs have been used in fracture non-unions. This is 
exemplified by the use of both BMP-7 and BMP-2 in long 
bone fracture non-unions [32-34]. Clinical studies looking at 
long bone non-union fractures treated with BMP, bone 
healing rates were between 75-100% and the mean healing 
times were all under 8 months [32, 33, 35-37]. The non-
union healing with conventional gold-standard treatment of 
autograft [34] reaches similar levels of 87-100%, however as 
mentioned earlier they also carry several risks such as donor 
graft morbidity [5]. 
2. Transforming Growth Factor-1 (TGF--1) 
 TGF- is a growth factor which helps stimulate cell 
replication and extracellular matrix formation [38]. 
Autologous chondrocytes obtained from MSCs can undergo 
expansion and proliferation in the presence of a 
chondrogenic medium containing TGF-1 to the 3D culture. 
MSCs have the capacity to synthesise all components of the 
normal articular cartilage matrix [39]. 
  A study by Guo et al. [40] investigated whether TGF-1 
modified MSCs to enhance the repair of full thickness 
articular cartilage damage in a rabbit model. TGF-1 is not 
only chondrogenic, but also has the ability to inhibit the 
alloreactive immune response. The MSCs transfected with 
TGF-1 gene were seeded onto a biomimetic scaffold (poly-
L-lysine coated polylactide (PLA)) in vitro and allografted 
into the cartilage defects. Macroscopic, histological and 
ultrasound studies were performed at specific follow-up 
times. The in vitro study showed that the proliferation and 
generation of cartilaginous matrix by the experimental group 
was substantially greater than in the control group, MSCs 
without TGF-1. Furthermore, the animal model studies 
provided evidence of surface hyaline cartilage-specific 
extracellular matrix synthesis and reconstruction of the 
subchondral bone at 24 weeks post-implantation. An 
important criterion of gene based tissue engineering is that 
growth factor delivery should have a sustained expression, as 
demonstrated [40]. 
  Another study [41] looked at chondrogenesis of MSCs in 
vitro using TGF-1 enhanced biphasic implants which were 
made up of a gel and a solid scaffold. The gel component in 
these implants ensures homogenous distribution of the cells. 
In addition, human and animal fibrin has proven useful in the 
storage and delivery of many growth factors [42]. The study 
showed that the biphasic implants embedded with locally 
releasing bioactive TGF-1 showed enhanced chondrogenic 
proliferation in vitro compared to the classical pellet culture. 
 Park  et al. described an enhanced neocartilage formation 
by rabbit MSCs using a hydrogel plus heparin-bound TGF- 
growth factor [43].
 The results indicated a long-term release 
of TGF- after complexation with chondroitin sulfate 
suitable for induction of chondrogenic differentiation of 
rabbit MSCs [44]. 
  The use of TGF- to augment the effect of the MSCs on 
the scaffold has thus, shown to enhance the recruitment, 
proliferation and differentiation of the bone marrow stem 
cells [45]. 
 TGF-1 has also been employed in inducing 
arthrofibrosis in a study by Watson et al. [46] and its 
potential as a pro-fibrotic in joint disease. The study 
investigated how sustained production of TGF-1 intra-
articularly drives chronic arthrofibrosis. A recombinant 
adenovirus gene vector to locally overexpress TGF-1 in a 
rat model and this induced a fibrotic condition that 
immobilised the injected joint. In 10 days, the proliferation 
of fibroblasts replaced all the normal anatomical structures 
and began to fuse with the articular cartilage, ligamentous 
and capsular fibrous tissue. Also, the levels of collagen I, III 
and V were elevated by 10-fold. At 30 days, the 
cartilaginous masses had penetrated the entire joint space 
and deposited a rich proteoglycan matrix and matrix 
metalloproteinases (MMPs) were shown to promote tissue 
remodelling on histological examination. 
3. Vascular Endothelial Growth Factor (VEGF) 
  Bone formation and angiogenesis are closely linked. 
Therapeutic angiogenesis is a new concept that promotes 
new blood vessel formation by delivering exogenous 
angiogenic growth factors to the tissue such as VEGF [47]. 
Before effective osteogenesis occurs, there needs to be the 
formation of new blood vessels that invade and mediate the 
supply of oxygen, nutrients and osteoprogenitor cells [48]. 
 Both  TGF-1 and VEGF were locally administered using 
transfected bone marrow stem cells to repair the anterior 
cruciate ligament using the Achilles tendon in a study by 
Wei  et al. [49]. The VEGF significantly improved 
revascularization of the graft but TGF-1 was needed to aid 
mechanical strength by regulating the formation and cross-
linkage of collagen type I and type III. The best mechanical 
properties of the graft were found to be at 24 weeks. Hence, 
the co-expression of these two genes was found to produce 
the best results. 
  In a study by Geiger et al. [50] large bone defects were 
treated with VEGF transfected bone marrow stem cells using 
a coralline scaffold (bone substitue). Four different groups 
were analysed. In the control, the scaffold was coated with a 
control-plasmid DNA. In group 2 it was coated with VEGF 
plasmid DNA, group 3 with MSC-transfected control 
plasmid and finally group 4 with both MSCs and the VEGF 
plasmid. The results showed that both the VEGF-transfected 
cell groups had increased vascularisation and osteogenesis. 
In addition, the VEGF plus MSC group led to more intense 
and homogenous vascularisation of the defect and fastest 
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4. Basic Fibroblast Growth Factor (bFGF) 
  It has been reported in two studies that the transfection of 
TGF-1 gene with MSCs can also induce them to express 
bFGF and VEGF [22, 51]. These can promote the 
regeneration of vasculature, thereby enhancing the 
osteogenic differentiation of MSCs. This was also supported 
by another study by Guo et al. [2], where bFGF transfected 
MSCs seeded on biomimetic biodegradable scaffolds were 
used to repair large segmental bone defects. Both the in vitro 
and  in vivo evidence pointed to significantly more bone 
formation and abundant active angiogenesis in the 
experimental groups. 
  In another study [52], different FGFs were added to a 
chondrogenic medium at different stages of development. 
This chondrogenesis in a pellet culture using transfected 
MSCs occurred by three stages as in embryonic skeletal 
development. These were: condensation, differentiation and 
hypertrophy which were clearly expressed as seen by the 
different levels of expression of collagen II and N-cadherin. 
During condensation, the cells expressed cell adhesion 
molecules which become downregulated as they 
differentiated to chondrocytes, forming a cartilage template. 
Next, the cartilage hypertrophied and finally, ossified. FGF 
receptor activation is associated with endochondral 
ossification during development. These receptors were 
initially discovered when it was found that their mutations 
caused abnormalities in skeletal development [53]. In the 
future, modulating the FGF signal to produce stage-specific 
differentiation in chondrogenesis remains to be explored. A 
better knowledge of as well as control over the FGF 
receptors will lead to further advancements in cartilage 
healing and extend to regeneration of other types of tissue. 
  We have previously shown that synovial fat pad derived 
MSCs expanded in fibroblast growth factor-2 (FGF-2) 
showed cell surface epitope expression similar to adult stem 
cells [54]. The synovial fat pad derived MSCs showed 
chondrogenic differentiation in cell aggregate cultures, and 
prior expansion with FGF-2 enhanced chondrogenesis.  
  Thus, the evidence from growth factor enhanced tissue 
engineering studies points to a great potential for bone, 
cartilage, tendon and muscle healing. 
CONCLUSIONS 
  Mesenchymal stem cells, that are the most commonly 
used type of cells can be easily isolated and cultured in vitro. 
Harnessing these osteoprogenitor cells that have the ability 
to differentiate into all the different cell lineages of the limb 
mesoderm gives them the potential to generate virtually 
billions of ex vivo-expanded MSCs that can be implanted at 
the site of the defect, hence a relatively non-invasive 
technique. However, being able to isolate a demonstrably 
pure, multipotent and self-renewing stem cell sub fraction 
from bone marrow stroma, or in fact any other tissue source 
continues. Future research should aim to focus on 
purification of these stem cells in addition to trying to fully 
understand the potential of these primitive cells so they can 
be harnessed to their full potential to enhance tissue repair. 
  Osteoconductive 3D constructs seeded with MSCs is a 
highly porous, biodegradable and biomechanically stable 
scaffold which does not evoke an immunogenic host cell 
response. These bio-engineered graft substitutes make an 
ideal alternative to the traditional bone/cartilage grafts, 
showing no donor site morbidity and being completely 
resorbed from the host after a period of time. Future 
strategies would involve designing a scaffold which provides 
stable fixation and maximised strength along with site-
specific formation of new skeletal tissue. 
  Growth factors contribute angiogenic and regenerative 
potential along with mechanical stability in the differentiated 
tissue. Harnessing this capacity of growth factors as 
extracellular signalling agents can be used for the 
differentiation of bone and other tissues to mimic the natural 
development process [55]. Gene-based delivery systems 
have aided the delivery of sustained quantities of these 
growth factors but further exploration of associated risks and 
benefits as a source for cell-based tissue regeneration in 
longitudinal animal studies is required. 
  Ultimately, there is a need for randomised controlled 
trials on human populations to apply these findings to a 
clinical setting. In addition, the cost benefit ratio will also 
need to be considered after sufficient trials have been carried 
out to validate the use of this technology over traditional 
methods of tissue reconstruction. 
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